With Serial Entrepreneur At Its Helm, Arrakis Raises $38m To Target RNA With Small Molecules

Serial entrepreneur Michael Gilman has taken the helm of another start-up; after selling Padlock to Bristol-Myers and Stromedix to Biogen, his new company Arrakis has raised a $38m Series A round with big biopharma backing.

DNA

Michael Gilman didn't have much time to enjoy "retirement" after Bristol-Myers Squibb Co. acquired his last company Padlock Therapeutics Inc. for up to $600m. Within months he was immersed in multiple new opportunities, the first of which, Arrakis Therapeutics, has closed a $38m Series A venture capital round.

The Bristol-Myers acquisition of Padlock was announced in March and by April, during his last week at BMS, Gilman heard...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip